

ANTIRETROVIRAL DRUGS FOR TREATING PREGNANT WOMEN AND PREVENTING HIV INFECTION IN INFANTS

Recommendations for a public health approach

2010 version



World Health
Organization

WHO Library Cataloguing-in-Publication Data

Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: recommendations for a public health approach. – 2010 version.

1.Anti-retroviral agents - pharmacology. 2.HIV infections - therapy. 3.HIV infections - prevention and control. 4.Disease transmission, Vertical - prevention and control. 5.Pregnant women. 6.Guidelines. I.World Health Organization.

ISBN 978 92 4 159981 8

(NLM classification: WC 503.2)

© World Health Organization 2010

All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: permissions@who.int).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Printed in France

ANTIRETROVIRAL DRUGS FOR TREATING PREGNANT WOMEN AND PREVENTING HIV INFECTION IN INFANTS

Recommendations
for a public health approach

2010 version



**World Health
Organization**



ACKNOWLEDGEMENTS

WHO would like to thank the following people.

Lynne M. Mofenson (Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, USA) for her outstanding contribution and support.

The core writing group members for their dedication and leadership: **François Dabis** (INSERM, Université Victor Segalen, Bordeaux 2, France), **James McIntyre**, chair, guidelines review meeting (Anova Health Institute, Johannesburg, South Africa) and **Lynne M. Mofenson**.

The GRADE review group from the University of California, San Francisco, USA: **George Rutherford**, **Gail Kennedy**, **Joy F. Mirjahangir**, **Amy Sturt**, **Jaco Homsy**, **Rachel King**, **Andy Anglemeyer**, **E. Kainne Dokubo**, **Gavrilah Wells**, **Joy Oliver**, **Karen Schlein**, **Lize van der Merwe**, **Jennifer S. Read** (Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, USA) and **Nandi Siegfried** (South African Cochrane Centre). Special thanks go to **Nancy Santesso** and **Holger Schünemann** (McMaster University, Canada) and **Mary Lou Lindegren** (US Centers for Disease Control and Prevention, USA).

The participants of the guidelines review meeting:

Civil society / PLHIV: **Jane Mwirumubi** (Kamwokya, Kampala, Uganda) and **Portia Ngcaba** (East London, South Africa).

Country representatives / programme experts: **Marcelo Araújo de Freitas** (STD and AIDS Department, Ministry of Health, Brazil), **Kevin M. De Cock** (US Centers for Disease Control and Prevention, KEMRI, Nairobi, Kenya), **Nonhlanhla Rosemary Dlamini** (Department of Health, South Africa), **Svitlana Komar** (Clinic for Treatment of HIV-infected Children, Ukraine), **Dorothy Mbori-Ngacha** (University of Nairobi, Nairobi, Kenya), **Elevanie Munyana** (Clinical Prevention Department, PMTCT at TRAC-Plus, Ministry of Health, Rwanda), **Sarah Shalongo** (Paediatric ARV, Ministry of Health and Social Services, Windhoek, Namibia), **Florence Soroses** (Global Fund, Ministry of Health and Social Services, Windhoek, Namibia) and **Nipunporn Voramongkol** (Department of Health, Ministry of Public Health, Thailand).

Content experts: **Elaine Abrams** (The International Center for AIDS Care and Treatment Programs, Mailman School of Public Health, Columbia University, New York, USA), **François Dabis**, **Laura A. Guay** (Elizabeth Glaser Pediatric AIDS Foundation, Washington DC, USA), **Louise Kuhn** (Gertrude H. Sergievsky Center, College of Physicians and Surgeons, Columbia University, New York, USA), **Marc Lallemand** (Programs for HIV Prevention and Treatment, Thailand), **James McIntyre**, **Lynne M. Mofenson**, **Roger Shapiro** (Harvard Medical School, Division of Infectious Diseases, Boston, USA) and **Jeffrey S. A. Stringer** (University of Alabama at Birmingham, Center for Infectious Disease Research in Zambia, Lusaka, Zambia).

Methodologists: Health systems - **Pierre Barker** (Department of Paediatrics, University of North Carolina, Chapel Hill, USA), GRADE - **Nancy Santesso**.

Implementing partners: **Omotayo Bolu** (Global AIDS Program, CDC, Atlanta, USA), **Margaret Brewinski** (USAID Office of HIV/AIDS, Washington DC, USA) and **René Ekpin** (UNICEF, New York, USA).

External peer reviewers: **Suna Balkan** (Médecins sans Frontières, Paris, France), **Marc Bulterys** (CDC China, Beijing, China), **Mary Glenn Fowler** (Makere University, Johns Hopkins University Research Collaboration, Kampala, Uganda), **Angela Mushavi** (PMTCT and Pediatric Treatment,

CDC - Namibia and Namibia Ministry of Health), **Sostena Romana** (Global PMTCT Initiative, Clinton Foundation HIV/AIDS Initiative, Boston, USA), **Landry Tsague** (UNICEF, Kigali, Rwanda) and regional office staff of the six WHO regions.

The guidelines writers: **Renaud Becquet** (INSERM, Centre de Recherche U897, Université Victor Segalen Bordeaux 2, Bordeaux, France) and **Stanley Luchters** (International Centre for Reproductive Health, Ghent University, Ghent, Belgium). Editing review: **Philippe Gaillard** (WHO Nairobi, Kenya) and **Mathew Chersich** (Centre for Health Policy, School of Public Health, University of Witwatersrand, South Africa).

The following WHO staff contributed to the development of these guidelines: **Siobhan Crowley (HIV)**, **Isseu Diop-Toure (AFRO)**, **Eleonora Marini (intern)**, **Boniface Dongmo Nguimfack (HIV)**, **Haileyesus Getahun Gebre (STB)**, **Reuben Granich (HIV)**, **Françoise Renaud-Théry (HIV)**, **Nigel Rollins (CAH)**, **Charles Sagoe-Moses (AFRO)**, **Annette Verster (HIV)**, **Isabelle de Vincenzi (RHR)** and **Marco Vitoria (HIV)**.

The work was coordinated by **Nathan Shaffer**, **Tin Tin Sint** and **Ying-Ru Lo** (Department of HIV/AIDS, WHO).

Funding to support the work came from the US President's Emergency Plan for AIDS Relief (PEPFAR), through the US Centers for Disease Control (CDC) and the US Agency for International Development (USAID), and from the United Nations Joint Programme on HIV/AIDS (UNAIDS).

TABLE OF CONTENTS

Acknowledgements	iii
Table of contents	v
Abbreviations and acronyms	vii
Summary of recommendations	1
Section I: Introduction and objectives	11
Introduction	11
Objectives of the guidelines.....	12
Target audience	13
Section II. Development of the guidelines and guiding principles	14
Development of the guidelines	14
Guiding principles	18
Section III: Antiretroviral drugs for treating pregnant women for their own health and to prevent HIV infection in their infants	20
Key recommendations	20
ART eligibility for pregnant women	20
ART regimens for pregnant women eligible for treatment	21
ART regimens for women of childbearing age receiving treatment for their own health...	26
Antiretroviral prophylaxis for infants born to women receiving ART.....	27
Clinical and laboratory monitoring of pregnant women receiving ART for their own health and their infants	34
Section IV: Maternal and infant ARV prophylaxis to prevent MTCT for HIV-infected pregnant women who do not need treatment for their own health	35
Key recommendations	35
ARV prophylaxis for women and their infants to reduce perinatal HIV transmission	36
Maternal AZT plus infant ARV prophylaxis to prevent MTCT (option A)	36
Maternal triple ARV prophylaxis to prevent MTCT (option B).....	41
Women diagnosed during labour or immediately postpartum.....	52
Clinical and laboratory monitoring of pregnant women receiving ARV prophylaxis and their infants	53
Section V: Special considerations	54
ARV regimens for women previously exposed to antiretroviral drugs.....	54
Women who acquire primary infection during pregnancy or breastfeeding.....	54
Women with anaemia.....	54
Women with HIV-2 infection	55
Women with active tuberculosis	56
Women with hepatitis B or hepatitis C virus coinfection	56
Pregnant women living with HIV who are injecting drug-users.....	57

Section VI: Safety and risk of resistance to antiretroviral drugs in pregnant women and their infants 59

 Safety and risk of resistance to nucleoside reverse transcriptase inhibitors (NRTIs)..... 60

 Safety and risk of resistance to non-nucleoside reverse transcriptase inhibitors (NNRTIs) 61

 Safety of protease inhibitors (PIs)..... 63

Section VII: Health systems considerations of ARV-based interventions for women and infants 66

Annexes

 Annex 1. Package of essential services for pregnant and postpartum women and their children 68

 Annex 2. Examples of GRADE evidence profiles for the key PICO questions 70

 Annex 3. Risk-benefit tables of key questions..... 76

 Risk-benefit table 1. When to start ART in HIV-1-infected pregnant women 76

 Risk-benefit table 2. What ART to give to HIV-infected pregnant women in need of treatment for their own health and what to give their infants 79

 Risk-benefit table 3. When to start maternal ARV prophylaxis in pregnancy for women not eligible for treatment 84

 Risk-benefit table 4. What ARV prophylaxis to give to pregnant women for PMTCT (for women not eligible for ART, with unknown eligibility or when ART is not available)..... 87

 Annex 4. Priorities for research..... 93

 Annex 5. Glossary..... 97

References 98

预览已结束，完整报告链接和

<https://www.yunbaogao.cn/report/index/report>